RxDoctor Payments Data

Nicholas Lacivita

Psychiatry · Brandon, MSNPI 1700451291

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 24.6% of the total. Reporting peaked in 2024 at $1,859 and has fallen 59.4% since, to $754 in 2025.

$4,362in general payments, 2019–2025

Across 139 payments — averaging $31.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Alkermes, Inc.$700
  • Johnson & Johnson$440
  • Neurocrine Biosciences, Inc.$417
  • Lundbeck LLC$406
  • E.r. Squibb & Sons, L.L.C.$327
  • plus $996 from 8 others

What the payments were for

  • Food & beverage$4,362100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,362 in reported general payments places this provider in the 85th percentile of 219 psychiatry providers in Mississippi.

See all psychiatry providers in Mississippi

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate19$162,257
Invega SustennaPaliperidone Palmitate19$48,409
AristadaAripiprazole Lauroxil14$44,217
VraylarCariprazine Hcl16$24,939
TrintellixVortioxetine Hydrobromide12$7,147
Chlorpromazine Hcl23$2,494
Haloperidol Decanoate33$1,507
Lurasidone Hcl18$1,396
Atomoxetine Hcl12$701
Duloxetine Hcl28$522
Divalproex Sodium25$434
Bupropion XlBupropion Hcl14$360
Quetiapine Fumarate24$346
Hydroxyzine Pamoate27$301
Aripiprazole20$287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$417$162,25719 claims
Johnson & JohnsonInvega Sustenna$440$48,40919 claims
Alkermes, Inc.Aristada$700$44,21714 claims
AbbVieVraylar$186$24,93916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 219 psychiatry providers in Mississippi.

Other psychiatry in Brandon

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →